Bristol-Myers Squibb Company (BMY)

NYSE - NYSE Real Time Price. Currency in USD
58.77+0.01 (+0.02%)
At close: 4:01 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close58.76
Bid58.77 x 100
Ask58.83 x 500
Day's Range58.54 - 59.40
52wk Range56.32 - 77.12
1y Target EstN/A
Market Cap98.2B
P/E Ratio (ttm)34.37
Avg Vol (3m)9,445,339
Dividend & Yield1.52 (2.59%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Reuters2 days ago

    Lung cancer doctors eye Merck's Keytruda over Bristol's Opdivo

    Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges, oncologists and analysts say. The yet-to-be-published studies involve drugs in a new class designed to enable the body's immune system to fight cancer. A recent trial of Merck's Keytruda showed that it worked better than chemotherapy as an initial treatment for advanced non-small cell lung cancer (NSCLC) in patients with high levels of a protein called PDL1, believed to help identify those most likely to benefit from this type of immunotherapy.

  • Investopedia2 days ago

    Top 5 Health Care Stocks of 2016 (AMGN, BMY)

    Discover why the baby boomers are benefiting the health care sector. Explore five health care stocks that are well positioned to meet customers' demands.

  • Market Realist3 days ago

    How Did Bristol-Myers Squibb Fare in 2Q16?

    Bristol-Myers Squibb (BMY) reported an increase of 17% in revenues at ~$4.9 billion during 2Q16.